Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Farmaco ; 46(3): 509-20, 1991 Mar.
Article in English | MEDLINE | ID: mdl-1892505

ABSTRACT

The HPLC technique for the isolation and quantitation of 5-fluoro-2-(5'-nitro-2'-furyl)benzimidazole (F-O-NO2), previously described by the same Authors, in biological samples from mice is reported. Evidence is given that the highest biological concentration and the time needed for reaching it depend both on the dose and on the administration route. In fact, almost the same maximal biological concentration of F-O-NO2 (about 0.18 micrograms/mouse) is reached after 60 min from either 40 mg/Kg IP or 200 mg/Kg os drug administration, whereas the maximal biological concentration of F-O-NO2 (5.75 micrograms/mouse) is reached after 30 min from 120 mg/Kg IP drug administration.


Subject(s)
Anti-Infective Agents/analysis , Benzimidazoles/analysis , Animals , Anti-Infective Agents/blood , Anti-Infective Agents/pharmacokinetics , Benzimidazoles/blood , Benzimidazoles/pharmacokinetics , Chromatography, High Pressure Liquid , Male , Mice , Organ Size , Tissue Distribution
2.
Farmaco Sci ; 42(7): 541-7, 1987 Jul.
Article in English | MEDLINE | ID: mdl-3311805

ABSTRACT

We have studied the possible in vitro and in vivo antibacterial activity of 5-fluoro-2-(5'-nitro-2'-furyl)benzimidazole (F-O-NO2). Our data demonstrate that F-O-NO2 is able to inhibit the in vitro growth of different mycetes and bacteria, including Candida albicans and Cryptococcus neoformans. We also tested the possible in vivo activity against Candida albicans. The results clearly show that treatment with F-O-NO2 is able to significantly augment the survival of all treated animals; in particular, when injected i.p. at the dose of 120 mg/kg, 30' or 1 hr after Candida albicans challenge, it givens a MST (Medium Survival Time) longer than 60 days. These data demonstrate that F-O-NO2 has antibacterial and antimycotic activity.


Subject(s)
Antifungal Agents , Benzimidazoles/pharmacology , Candida albicans/drug effects , Animals , Antifungal Agents/chemical synthesis , Bacteria/drug effects , Benzimidazoles/chemical synthesis , Cryptococcus neoformans/drug effects , Mice , Microbial Sensitivity Tests
3.
Farmaco Sci ; 36(5): 315-33, 1981 May.
Article in French | MEDLINE | ID: mdl-7238851

ABSTRACT

Sixty five new derivatives of ethyl-1H-indazole-3-carboxylate are described; they contain in N1 various aliphatic or aromatic acyl radicals. Moreover halogens or methyl groups are present as substituents at the 5 position or methyl groups at 5,6. The synthesis of seven 1H-indazole-3-hydroxamic acids, substituted at 6 and/or 5 as above, is also described. Some of the synthesized derivatives have preliminarily been tested on rats to investigate acute toxicity, possible antiarthritic effects on primary or secondary arthritis, and their action on weight gain. Some of these indazole derivatives had an antiarthritic effect at doses much lower than the toxic ones; among the compounds tested up to now, the ethyl-5-methyl-N1-p-chlorobenzoyl-1H-indazole-3-carboxylate gave the best results. Weight gain as not affected by any of the examined compounds.


Subject(s)
Anti-Inflammatory Agents/chemical synthesis , Indazoles/chemical synthesis , Pyrazoles/chemical synthesis , Animals , Arthritis, Experimental/drug therapy , Carboxylic Acids/chemical synthesis , Carboxylic Acids/pharmacology , Hydroxamic Acids/chemical synthesis , Hydroxamic Acids/pharmacology , Indazoles/pharmacology , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...